Results 61 to 70 of about 1,988,593 (307)

Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV [PDF]

, 2014
The impact of imatinib dose on response rates and survival in older patients with chronic myeloid leukemia in chronic phase has not been studied well. We analyzed data from the German CML-Study IV, a randomized five-arm treatment optimization study in ...
Annette Schreiber, Lothar Müller, Hofmann, Wolf-Karsten, Hanfstein, Benjamin, Krause, Stefan W., Benjamin Hanfstein, Müller, Martin C, Michael Lauseker, Kremers, Stephan, Bernd Hertenstein, Hasford, Joerg, Rüdiger Hehlmann, Joerg Hasford, Wolf-Karsten Hofmann, Schlag, Rudolf, Hehlmann, Rüdiger, null null, Stephan Kremers, Müller, Lothar, Mathias Hänel, Hänel, Mathias, Nadine Pletsch, Martin C. Müller, Gabriela M. Baerlocher, Dominik Heim, Saußele, Susanne, Krause, Stefan W, Hartmut Link, Pfirrman, Markus, Baerlocher, Gabriela M., Stefan W. Krause, Pfirrmann, Markus, Wernli, Martin, Martin Wernli, Markus Pfirrmann, Hertenstein, Bernd, Link, Hartmut, Rudolf Schlag, Hermann Einsele, Pletsch, Nadine, Schreiber, Annette, Elisabeth Lange, Müller, Martin C., Lange, Elisabeth, Hochhaus, Andreas, Lida Kalmanti, Lauseker, Michael, Kalmanti, Lida, Ulrike Proetel, Heim, Dominik, Susanne Saußele, Proetel, Ulrike, Einsele, Hermann, Andreas Hochhaus   +53 more
core   +2 more sources

Unraveling the epigenetic code in cancer cell–tumor microenvironment crosstalk

Molecular Oncology, EarlyView.
Epigenetic regulation is a key driver of cancer development and progression. Diverse epigenetic alterations in cancer cells and components of the tumor microenvironment (TME) orchestrate their communication through multiple mechanisms. We discuss how the epigenetic code coordinates bidirectional cancer cell–TME crosstalk to promote cancer progression ...
Ji Hoon Park, Mi‐Young Kim
wiley   +1 more source

Deregulated expression of Cdc6 as BCR/ABL-dependent survival factor in chronic myeloid leukemia cells

Tumor Biology, 2017
Chronic myeloid leukemia is characterized by the presence of the reciprocal translocation t(9;22) and the BCR/ABL oncogene. The BCR/ABL oncogene activates multiple signaling pathways and involves the dysregulation of oncogenes during the progression of ...
Jia-Hua Zhang, Yan-Li He, Rui Zhu, Wen Du, Jun-Hua Xiao   +4 more
doaj   +1 more source

Evolutionary Dynamics of Chronic Myeloid Leukemia [PDF]

Genes & Cancer, 2010
Cancer is an evolutionary process that arises due to mutations and expands through the selection of clones with higher reproductive success that will outcompete their peers. Most tumors require many mutations to explain the cancer phenotype, making it difficult to identify the gene(s) that confer the reproductive fitness to the clone.
Dingli, D., Lenaerts, Tom, Traulsen, Arne, Pacheco, Jorge J.M.   +3 more
openaire   +5 more sources

Staging of chronic myeloid leukaemia.

, 1981
The prognostic value of nine clinical and haematological features, recorded at diagnosis in chronic myeloid leukaemia (CML), was analysed in two distinct series of patients. One series (116 cases) was collected at a single hospital over a 12-year period.
Corbelli, G, Baccarani, M, the Italian Cooperative Study Group on Chronic Myeloid Leukemia, Tura, S, LIBERATI, Anna Marina   +4 more
core   +1 more source

Mechanisms and therapeutic opportunities of the ribotoxic stress response in cancer

Molecular Oncology, EarlyView.
Cancer cells' high translational demand creates opportunities to therapeutically target ribosome function. Ribosome stalling and collisions activate ZAKα and the ribotoxic stress response (RSR), which can trigger rapid, p53‐independent apoptosis in cancer.
Anastassiya Kim, Maryam Aslam, Elouise Torruella, Alphons Sony, Asif Rahman, Simira Smith, Columba de la Parra, Moira Sauane   +7 more
wiley   +1 more source

TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA [PDF]

Mediterranean Journal of Hematology and Infectious Diseases, 2014
The first treatment of chronic myeloid leukemia (CML) included spleen x-radiation and conventional drugs, mainly Busulfan and Hydroxyurea. This therapy improved the quality of life during the chronic phase of the disease, without preventing nor significantly delaying the progression towards advanced phases.
BACCARANI, MICHELE, CASTAGNETTI, FAUSTO, GUGLIOTTA, GABRIELE, PALANDRI, FRANCESCA, ROSTI, GIANANTONIO   +4 more
openaire   +4 more sources

One size does not fit all: An in vitro evaluation of the effects of bezafibrate and medroxyprogesterone acetate on human SH‐SY5Y and U‐87 MG cancer cells

FEBS Open Bio, EarlyView.
Drugs previously repurposed to target blood cancers reduced neuroblastoma and glioblastoma cell growth and viability. However, their levels of anticancer activity were different and their clinical application may be problematic due to side effects at effective doses.
Abhishek Kharawatkar, Francesco Michelangeli, Farhat Latif Khanim, Christopher Martin Bunce, William Eustace Basil Johnson   +4 more
wiley   +1 more source

PDGFRα promoter polymorphisms and expression patterns influence risk of development of imatinib-induced thrombocytopenia in chronic myeloid leukemia: A study from India

Tumor Biology, 2017
Platelet-derived growth factor receptor has been implicated in many malignant and non-malignant diseases. Platelet-derived growth factor receptor-α is a tyrosine kinase and a side target for imatinib, a revolutionary drug for the treatment of chronic ...
Sameer Ahmad Guru, Rashid Mir, Musadiq Bhat, Imtiyaz Najar, Mariyam Zuberi, Mamta Sumi, Mirza Masroor, Naresh Gupta, Alpana Saxena   +8 more
doaj   +1 more source

Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia

Haematologica, 2012
It was recently recognized that some chronic myeloid leukemia patients with a complete molecular response could sustain that response after discontinuation of imatinib.
Naoto Takahashi, Taiichi Kyo, Yasuhiro Maeda, Takashi Sugihara, Kensuke Usuki, Tatsuya Kawaguchi, Noriko Usui, Shinichiro Okamoto, Yokiko Ohe, Shigeki Ohtake, Kunio Kitamura, Masahide Yamamoto, Hirofumi Teshima, Toshiko Motoji, Toshiharu Tamaki, Kenichi Sawada, Kazuma Ohyashiki   +16 more
doaj   +1 more source